Subscribe
shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
25 January 2022Big PharmaMuireann Bolger

Mylan gets green light to challenge Neurim melatonin patent

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent